following the announcement that Novo Nordisk (NVO) and Eli Lilly (LLY) have negotiated to reduce the price of their GLP-1 weight loss drugs and agreed to make the drugs available directly to consumers through TrumpRx when the site is expected to go live to start 2026, Needham analyst Ryan MacDonald is reiterating a Hold rating on Hims & Hers Health (HIMS), arguing that the price cuts limit the company’s pricing advantage of their personalized GLP-1s. This increases Hims’ dependence on going to market with a branded GLP-1 manufacturer to remain competitive in the evolving weight loss market, the analyst contends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Sell Recommendation for Hims & Hers Health Amid Competitive Pricing Pressures and Projected Decline
- TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi
- Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire
- Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism
- Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy